SGS Opens Central & Eastern Europe Offices for Clinical Trial Management.
Geneva, Switzerland-April 25, 2008-As a further step in the initiative to expand its Global Clinical Development (GCD) services, SGS Life Science Services has opened three new offices in Poland, Czech Republic, and Romania. The offices located in Prague, Warsaw, and Bucharest, respectively, will provide services for clinical trial monitoring, study feasibility, and site selection, as well as support the regulatory aspects in these countries.
“The opening of the new offices addresses the request of many of our sponsors to conduct trials in Central and Eastern Europe in order to benefit from the vast pool of treatment naïve patients, faster enrolment times, and the cost benefits these countries offer,” said Luc Braeken, vice president of global clinical development. “Highly qualified and motivated investigators, low drop out rates of enrolled patients, and the high quality of the clinical data are additional advantages of conducting trials in Central and Eastern Europe.”
The offices are staffed with highly knowledgeable teams with broad experience in conducting clinical trials in the pharmaceutical and CRO industry as well as in academia. Lead by seasoned MDs, the teams cover a wide range of therapeutic areas with special emphasis in CNS, infectious disease, and cardiovascular disease, SGS’ areas of core expertise.Complementary services including project management, data management and statistics, regulatory affairs, and medical affairs will be provided from SGS’ main office for GCD in Belgium with more than 400 people.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.